AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03909256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTRI-HAB
Description: The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian.
Study NCT02302820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advance Care Planning Intervention
Description: ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids.
Study NCT00587054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Description: Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines.
Study NCT00056966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
Study NCT00521014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00521014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00521014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00521014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00521014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00521014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00521014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00521014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Study NCT03204903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
Study NCT03204903 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
Study NCT02865928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Same injection technique as intervention arm with normal saline
Study NCT03609710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transanal tube placement
Description: Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
Study NCT03609710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left colic artery preservation
Description: Left colic artery preservation during operation for lower rectal cancer
Study NCT03609710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anastomotic reinforcing sutures
Description: Anastomotic reinforcing sutures during operation for lower rectal cancer
Study NCT03609710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic surgery
Description: Robotic low anterior resection for rectal cancer
Study NCT03609710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Robotic low anterior resection for rectal cancer
Study NCT03152110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO.
Study NCT02082665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin10 mg tablet
Description: Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
Study NCT02082665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg syrup
Description: Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
Study NCT02082665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 75 mg capsule
Description: Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
Study NCT01905514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: internet mobile application
Study NCT05155839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG001
Description: Administrated intravenously
Study NCT03304392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
Study NCT03304392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
Study NCT01901367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Receive nutritional intervention
Study NCT01901367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Receive exercise intervention
Study NCT01901367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up care
Description: Receive booster follow-up sessions from the nutritionist and exercise physiologist
Study NCT01901367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive phone counseling with a trained health coach
Study NCT01901367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01901367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01901367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT04630444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 30 PTSD patients with riluzole 100 mg daily (50 mg bid).
Study NCT01634100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid
Study NCT01634100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin
Study NCT01634100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: BI Drug
Study NCT01634100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (BI 10773)
Description: BI Drug
Study NCT00744692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unrelated Umbilical Cord Blood Transplant
Description: Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
Study NCT00744692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Study NCT00997828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus-eluting stent
Description: Xience V stent
Study NCT00997828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass graft surgery
Description: coronary artery bypass graft surgery
Study NCT01934608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refill synch
Study NCT02911051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actreen Hydrolite Cath
Description: Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
Study NCT02768844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Vibrotactile Stimulation (SVS)
Description: The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
Study NCT02768844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Absence of mattress Stochastic Vibratory Stimulation (SVS)
Study NCT01140464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative care
Description: Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
Study NCT01140464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Provision of screening results to provider, teen and parent with recommendation to seek further care
Study NCT04410835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Online Survey
Description: Psychological questionnaires
Study NCT00959894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (Intelence)
Description: Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
Study NCT00959894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
Study NCT03965546 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with ET140202-T cell
Description: 1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion
Study NCT03965546 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAE combined with ET140202-T cell
Description: 1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)
Study NCT03965546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET140202-T cell
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
Study NCT04391153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with tissue sampling
Description: Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
Study NCT01902836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus DLE
Description: Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month
Study NCT01902836 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment plus placebo
Description: Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
Study NCT02982642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1612 capsule
Description: Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
Study NCT02982642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
Study NCT00427375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local rectal excision
Description: New surgical option in good responders after neoadjuvant treatment for low rectal cancer
Study NCT00427375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision
Description: standard surgery
Study NCT00952419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine
Description: 0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
Study NCT00952419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine
Description: 0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
Study NCT00952419 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution (placebo)
Description: 0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
Study NCT04162912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing tailored Advance Care Planning
Description: The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
Study NCT04955197 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: exfoliated cytology
Description: Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
Study NCT02954731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP-CBT
Description: Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy
Study NCT02954731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-CBT
Description: Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
Study NCT01312272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
Study NCT01312272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo nasal spray
Description: A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
Study NCT00056966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day-8 through Day-5 30 mg/m2
Study NCT00056966 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Day-1 single dose 450 cGy
Study NCT00056966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count >2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count >2 x 108/kg) will be substituted.
Study NCT01780675 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Prophylactic Cranial Irradiation
Study NCT01780675 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Hippocampal Avoidance PCI
Study NCT00754000 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: AE monitoring and EPIC QOL survey
Study NCT02972359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid
Description: Neridronic acid administered as intravenous infusion.
Study NCT04518813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Investigational Medical Device collecting Raman data from tissue
Study NCT02928172 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: qCON-qNOX
Description: Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
Study NCT02928172 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BIS
Description: Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
Study NCT00459524 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking about 30 minutes to complete.
Study NCT00459524 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurocognitive Testing
Description: Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.